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Bioreductive anti-tumour agents are a new class of anticancer
drugs, that have different chemical structures, but all require
reductive activation by intracellular enzymes (Workman et al,
1993; Adams et al, 1994). These drugs are generally used to treat
solid tumours, as they are often more toxic under hypoxic condi-
tions (Workman et al, 1993). The prototype drug in this class is
mitomycin C (MMC) (Rockwell et al, 1993), which is used in the
treatment of breast (Hortobagyi, 1993), non-small-cell lung
(Spain, 1993), head and neck (Coia, 1993), colorectal (Cummings
et al, 1993) and gastric (Fujita et al, 1998) cancer. Interest in bio-
reductive agents has been raised by recent studies of combination
treatment of MMC with radiation (Boyer, 1997), and by new
agents, such as 3-hydroxymethyl-5-aziridinyl-1-methyl-2(1H-
indole-4,7-dione)prop-b-en-a-ol (EO9) (Schellens, 1994) and tira-
pazamine (Bedikian et al, 1997; Miller et al, 1997). The
one-electron reducing enzyme, NADPH:cytochrome P450 reduc-
tase (EC 1.6.2.4), may be the most important activating enzyme
for MMC (Rockwell, 1993), but NAD(P)H:(quinone acceptor)
oxidoreductase [EC 1.6.99.2] (DT-diaphorase), a two-electron
reducing enzyme, is also a major activator in many systems
(Begleiter et al, 1989, 1992; Riley and Workman, 1992; Ross et al,
1993). Other enzymes, such as NADH:cytochrome b5 reductase
[EC 1.6.2.2] (Hodnick, 1993) and xanthine dehydrogenase [EC
1.1.1.204] (Gustafson and Pritsos, 1992) may also play a role in
activating MMC. Following activation, MMC can produce DNA
cross-links (Tomasz et al, 1987; Ross, 1993) and DNA strand
breaks (Lown et al, 1976; Pritsos et al, 1986); however, cross-
linking appears to be the most important mechanism for anti-
tumour activity (Rockwell et al, 1993).
DT-diaphorase is a flavoprotein that catalyses two-electron
reduction of quinones, quinone imines and nitrogen-oxides (Riley
and Workman, 1992). It is also a phase II enzyme that detoxifies
xenobiotics and carcinogens and protects cells from tumourigen-
esis (Beyer et al, 1988; Riley and Workman, 1992). Several
diaphorases are known in humans, but NQO1 gene is the most
extensively studied and seems to be the most important for activa-
tion of bioreductive agents (Jaiswal et al, 1990; Jaiswal, 1991;
Belinsky and Jaiswal, 1993). Tumour cells generally have higher
enzyme activity than the corresponding normal cells, but enzyme
levels in primary tumours are low compared to levels in some
tumour cell lines (Belinsky and Jaiswal, 1993; Ross et al, 1994;
Smitskamp-Wilms et al, 1995). DT-diaphorase can be induced in
many tissues by a wide variety of chemicals, including 1,2-
dithiole-3-thione (D3T) (Egner et al, 1994), quinones, isothio-
cyanates, diphenols and Michael reaction acceptors (Prestera et al,
1993), many of which are dietary components. Much attention has
been focused on the use of inducers of DT-diaphorase and other
phase II detoxifying enzymes in cancer prevention. Oltipraz, a
D3T analogue, has been shown to induce phase II detoxifying
enzymes and is currently undergoing clinical trials as a chemopre-
ventive agent (Kensler and Helzlsouer, 1995). Isothiocyanates like
sulforaphane, which is found in broccoli, can also induce phase II
enzymes (Prestera et al, 1993; Manson et al, 1997), and have been
shown to prevent the formation of carcinogen-induced tumours in
animals (Zhang et al, 1994).
DT-diaphorase plays an important role in activating bioreduc-
tive anti-tumour agents like MMC (Begleiter et al, 1989; Ross et
al, 1993; Mikami et al, 1996; Nishiyama et al, 1997), EO9 (Plumb
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Street, Winnipeg, Manitoba, Canada R3E 0V9et al, 1994), streptonigrin (Beall et al, 1996) and RH1 (Winski et
al, 1998). Cell lines with high levels of DT-diaphorase are more
sensitive to MMC (Begleiter et al, 1989; Ross et al, 1993; Mikami
et al, 1996), and studies have shown a good correlation between
the level of DT-diaphorase activity and the sensitivity to MMC in
human tumour cell lines (Fitzsimmons et al, 1996). Transfecting
the NQO1 gene into Chinese hamster ovary cells (Belcourt et al,
1996) and gastric carcinoma (Mikami et al, 1996) increased MMC
cytotoxic activity to the cells.
Previously, we showed that D3T selectively increased the
activity of DT-diaphorase in L5178Y murine lymphoma cells
compared to mouse marrow cells. Pretreating these cells with D3T
resulted in a twofold increase in MMC and a sevenfold increase in
EO9 cytotoxicity with no effect on marrow toxicity (Begleiter et al,
1996). We also found that D3T induced DT-diaphorase activity in
28 of 38 human tumour cell lines representing ten tissue types
(Doherty et al, 1998). Induction of DT-diaphorase activity in
human tumour cells by D3T significantly increased the cytotoxicity
of EO9 in these cells with no increase in toxicity to normal kidney
cells (Doherty et al, 1998).
These findings indicate that inducers of DT-diaphorase could be
used to enhance the anti-tumour efficacy of bioreductive agents. In
this study, we investigated combination treatment of MMC and
D3T in variety of human tumour cell lines, and studied dietary and
pharmaceutical inducers of DT-diaphorase in human tumour cells.
Although these inducers have been extensively studied in chemo-
prevention, they have not been investigated in combination with
bioreductive agents.
MATERIALS AND METHODS
Materials
Cell culture media and fetal bovine serum (FBS) were obtained
from GibcoBRL (Grand Island, NY, USA). All reagents for the
DT-diaphorase assay, 3-[4,5-dimethythiazol-2yl]-2,5-diphenyl-
tetrazolium bromide (MTT), 13-cis-retinoic acid, genistein,
ursolic acid, ibuprofen, caffeic acid, folic acid and MMC were
from Sigma (St Louis, MO, USA). Sulforaphane was purchased
from LKT Labs, Inc. (St Paul, MN, USA). Protein concentration
was measured using the Bio-Rad DC Kit (Bio-Rad, Mississauga,
ON, Canada) with g-globulin as standard. Vitamin K, dimethyl
maleate (DMM), dimethyl fumarate (DMF), propyl gallate (PG),
chalcone and aspirin were purchased from Aldrich (St Louis, MO,
USA). MethoCult GF H4434 was obtained from Stem Cell
Technologies Inc (Vancouver, BC, Canada). MMC was dissolved
in phosphate-buffered saline (PBS): dimethyl sulphoxide (DMSO)
(1:1, v/v). The final concentration of DMSO did not exceed 1%.
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Figure 1 Combination therapy with D3T and MMC in H661, human non-
small-cell lung cancer cells. Cells were incubated at 37°C with, or without,
50 mM D3T for 48 h, then were treated with various concentrations of MMC
for 1 h. Surviving cell fraction was determined by MTT assay. DT-diaphorase
activity was measured as described in Materials and Methods and is shown
in the inserted Figure. Data represent the mean ± s.e.m. of five
determinations. The lines are linear regression lines. Two-tailed t-tests were
used to determine the significance of the difference of the DT-diaphorase
activities. (*P < 0.05)
Figure 2 Combination therapy with PG, D3T, or DMM, and MMC in T47D,
human breast cancer cells. Cells were incubated with, or without, 10 mM PG,
75 mM D3T or 50 mM DMM for 48 h at 37°C, then were treated with various
concentrations of MMC for 1 h. Surviving cell fraction was determined by
MTT assay. DT-diaphorase activity was measured as described in Materials
and Methods and is shown in the inserted Figure. Data represent the mean ±
s.e.m. of three to eight determinations. The lines are linear regression lines.
ANOVA analysis was used to determine the significance of the difference of
the DT-diaphorase activities. (*P <0.05)
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NCI-H661, non-small-cell lung carcinoma cells were obtained
from American Type Culture Collection (Rockville, MD, USA)
and were grown in RPMI-1640 and 10% FBS. HCT116, colon
carcinoma cells and SK-MEL-28, malignant melanoma cells, were
from American Type Culture Collection and were grown in
DMEM/F12 (1:1) and 10% FBS. AGS, gastric adenocarcinoma
cells, were obtained from Dr JA Wright (Manitoba Institute of Cell
Biology, Winnipeg, MB, Canada) and were grown in RPMI-1640
and 10% FBS. T47D, breast ductal carcinoma cells, were from Dr
S Mai (Manitoba Institute of Cell Biology) and were grown in
RPMI-1640 and 10% FBS. HS578T, breast ductal carcinoma cells,
were obtained from Dr S Pan (Greenebaum Cancer Center,
Baltimore, MD, USA) and were grown in DMEM/F12 (1:1) and
10% FBS. Normal human bone marrow was obtained from
marrow donated for transplantation and marrow cells were isolated
by Ficoll–Hypaque separation (Begleiter et al, 1995). Marrow
cells were cultured in RPMI-1640 and 10% FBS.
Induction of DT-diaphorase
Cells were incubated with, or without, DT-diaphorase inducers at
37°C in 5% carbon dioxide for 48 h. The concentrations of
inducers used were not toxic to the cells during the incubation
time. Following incubation, cells were washed with PBS,
suspended in 200 ml of 0.25 M sucrose, sonicated and stored at
–80°C. Protein concentration was measured using the Bio-Rad DC
Kit with g-globulin as standard, then DT-diaphorase activity was
measured spectrophotometrically by a modification of the proce-
dure of Prochaska and Santamaria (Doherty et al, 1998; Prochaska
et al, 1988) using menadione as the electron acceptor. DT-
diaphorase activity was reported as dicoumarol-inhibitable activity
and expressed as nmol min–1 mg protein–1. A dicoumarol concen-
tration of 10 mM was used.
Enzyme assays
T47D cells were incubated with, or without, 50 mM DMM for 48 h.
Glutathione S-transferase (GST) activity was measured in super-
natant from cell sonicates by a spectrophotometric procedure using
1-chloro-2,4-dinitrobenzene as substrate (Habig et al, 1974).
NADPH:cytochrome P450 reductase activity was measured in
supernatant from cell sonicates by a spectrophotometric assay
using cytochrome c as the electron donor (Strobel and Digman,
1978). NADH:cytochrome b5 reductase activity was determined
by a previously described spectrophotometric procedure (Barham
et al, 1996). Xanthine dehydrogenase activity was measured using
a spectrophotometric method, in which xanthine dehydrogenase
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Figure 3 Combination therapy with D3T and MMC in HS578T, human
breast cancer cells. Cells were incubated at 37°C with, or without, 100 mM
D3T for 48 h, then were treated with various concentrations of MMC for 1 h.
Surviving cell fraction was determined by MTT assay. DT-diaphorase activity
was measured as described in Materials and Methods and is shown in the
inserted Figure. Data represent the mean ± s.e.m. of three to six
determinations. The lines are linear regression lines. Two-tailed t-tests were
used to determine the significance of the difference of the DT-diaphorase
activities. (*P < 0.05)
Figure 4 Combination therapy with D3T and MMC in HCT116, human colon
cancer cells. Cells were incubated at 37°C with, or without, 50 mM D3T for
48 h, then were treated with various concentrations of MMC for 1 h. Surviving
cell fraction was determined by MTT assay. DT-diaphorase activity was
measured as described in Materials and Methods and is shown in the
inserted Figure. Data represent the mean ± s.e.m. of four to six
determinations. The lines are linear regression lines. Two-tailed t-tests were
used to determine the significance of the difference of the DT-diaphorase
activities. (*P < 0.05)
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the formation of uric acid from xanthine in the presence and
absence of NAD+ (Gustafson et al, 1992).
Cytotoxicity studies
Tumour cells were incubated with, or without, inducers for 4 8 h
and then were treated with various concentrations of MMC for  1 h
at 3 7 °C. The surviving cell fraction was determined by MTT assay
(Kirkpatrick et al, 1990; Johnston et al, 1994) after 4–9 days; this
length of time was su fficient to allow at least three cell doublings.
Normal human marrow cells were treated with D3T for 4 8 h, and
then incubated with various concentrations of MMC for  1 h. The
surviving cell fraction was determined by methylcellulose clono-
genic assay (Begleiter et al, 1995). The D0 (concentration of drug
required to reduce the surviving cell fraction to 0.37) was calcu-
lated from the linear regression line of the surviving cell fraction
versus drug concentration curve.
RESULTS
Combination treatment with D3T and MMC
H661, human non-small-cell lung cancer cells, were incubated
with, or without, 5 0m MD3T and then were treated with MMC.
DT-diaphorase activity was increased from  1 17. 2  ±8.8 to
292. 0  ±14. 0nmol min –1 mg protein–1 (P< 0.001), and the cytotox-
icity of MMC was increased by 2.3-fold (Figure 1). The D0 was
3.2 4  ±0.19  m Mwithout D3T and 1.4 3 ±0.15  m Mwith D3T
(P< 0.001) ( Table 1).
T47D, human breast cancer cells, were incubated with, or
without, 75  m MD3T and then were treated with MMC. D T-
diaphorase activity was increased from 30. 0  ±0.8 to 100. 0  ±1.5
nmol min–1 mg protein–1 (P< 0.001), and the cytotoxicity of MMC
was increased by 2.4-fold (Figure 2). The D0 was 3.2 7 ±0.2 0m M
without D3T and 1.3 4 ±0.1 3m Mwith D3T (P< 0.001) ( Table 1).
HS578 T, human breast cancer cells, were incubated with, or
without, 10 0m MD3T and then were treated with MMC. D T-
diaphorase activity was increased from 237. 9  ±13.9 to 420. 8 ±19.0
nmol min–1 mg protein–1 (P< 0.001), and the cytotoxicity of MMC
was increased by 40% (Figure 3). The D0 was 3.7 2 ±0.30 m M
without D3T and 2.63 ±0.1 0m Mwith D3T (P< 0.01) ( Table 1).
HCT 1 16, human colon cancer cells, were incubated with, or
without, 5 0m MD3T and then were treated with MMC. D T-
diaphorase activity was increased from  1 18. 0  ±17.9 to 267. 0  ±56.3
nmol min–1 mg protein–1 (P< 0.05), and the cytotoxicity of MMC
was increased by twofold (Figure 4). The D0 was 3.31  ±0.25  m M
without D3T and 1.67  ±0.1 1  m Mwith D3T (P< 0.001) ( Table 1).
SK-MEL-28, human melanoma, were incubated with, or without,
5 0m MD3T and then were treated with MMC. D T-diaphorase
1226 X Wang et al
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Figure 5  Combination therapy with D3T and MMC in SK-MEL-28, human melanoma cells and AGS, human stomach cancer cells. SK-MEL-28 cells were
incubated at 37°C with, or without, 50m MD3T for 48h, then were treated with various concentrations of MMC for 1h. AGS, human stomach cancer cells were
incubated at 37°C with, or without, 25m MD3T for 48h, then were treated with various concentrations of MMC for 1h. Surviving cell fraction was determined by
MTT assay. DT-diaphorase activities were measured as described in Materials and Methods and are shown in the inserted Figures. Data represent the mean ±
s.e.m. of four determinations. The lines are linear regression lines. Two-tailed t-tests were used to determine the significance of the difference of the DT-
diaphorase activities in control and D3T treated cells. (*P <0.05)activity was increased from 270.0 ± 14.7 to 622.2 ± 22.9 nmol min–1
mg protein–1 (P < 0.001). AGS, human gastric cancer cells, were
incubated with, or without, 25 mM D3T and then were treated with
MMC. DT-diaphorase activity was increased from 216.5 ± 14.4 to
413.8 ± 13.4 nmol min–1 mg protein–1 (P < 0.001). However, there
was no significant increase in MMC cytotoxicity in either cell line
(Figure 5 and Table 1).
Induction of DT-diaphorase by dietary inducers in T47D
human tumour cells
The ability of dietary components and pharmaceuticals to induce
DT-diaphorase was examined in T47D human breast cancer cells.
The base level of DT-diaphorase in this cell line was 27.8 ± 1.2
nmol min–1 mg protein–1, and eight of 14 inducers showed signifi-
cant induction of enzyme activity (Table 2). The induced enzyme
levels ranged from 40.8 ± 1.2 to 128.5 ± 5.6 nmol min–1 mg
protein–1. The best inducers were DMM and DMF, with induced
enzyme levels of 121.0 ± 3.9 and 128.5 ± 5.6 nmol min–1 mg
protein–1 respectively.
Combination treatment of MMC with dietary inducers
T47D cells were incubated with, or without, 10 mM PG or 50 mM
DMM and then were treated with MMC. DT-diaphorase activity
increased from 30.0 ± 0.8 to 81.1 ± 2.8 and 121.0 ± 3.9 nmol min–1
mg protein–1 (P< 0.001), and the cytotoxicity of MMC was increased
by two- and threefold for PG and DMM respectively (Figure 2). The
D0 was 3.27 ± 0.20 mM with MMC alone, 1.85 ± 0.14 mM with PG
and 1.13 ± 0.09 mM with DMM (P < 0.001) (Table 1).
Effect of DMM on NADPH:cytochrome P450 reductase,
GST, NADH:cytochrome b5 reductase and xanthine
dehydrogenase activity
Incubation with 50 mM DMM at 37°C for 48 h had no significant
effect on the levels of NADPH:cytochrome P450 reductase and
NADH:cytochrome b5 reductase activity in T47D cells. The
activity of xanthine dehydrogenase was too low to be detected in
this cell line. There was a small increase in GST activity after incu-
bation with DMM with GST levels increasing from 20.2 ± 0.6 to
24.0 ± 1.1 nmol min–1 mg protein–1 (P < 0.05).
Bone marrow toxicity
Normal human marrow cells were incubated with 100 mM D3T and
then were treated MMC. DT-diaphorase activity increased from
1.9 ± 0.3 to 12.7 ± 2.4 nmol min–1 mg protein–1 (P < 0.005) (Figure
6). The surviving cell fraction of human marrow progenitor cells
(CFU-G, CFU-M, CFU-GM, CFU-E and BFU-E) was determined
by methylcellulose clonogenic assay. The D0 was 4.66 ± 0.41 mM
without D3T and 2.95 ± 0.23 mM with D3T (P < 0.05) (Figure 6
and Table 1). There was no obvious selective effect on any of the
progenitor cell types.
DISCUSSION
DT-diaphorase is a highly inducible enzyme that plays an impor-
tant role in activation of bioreductive anti-tumour drugs. It is also
a phase II detoxifying enzyme, which prevents carcinogenesis
by detoxifying reactive carcinogens. Elevated levels of DT-
diaphorase activity have been shown to increase the cytotoxicity of
MMC (Begleiter et al, 1989; Ross et al, 1993). We have previously
shown that pretreatment with D3T, an inducer of DT-diaphorase,
significantly increased the cytotoxic activity of E09 in mouse
(Begleiter et al, 1996) and human tumour cells (Doherty et al,
1998), with little or no effect on normal mouse marrow (Begleiter
et al, 1996) or normal human kidney cells (Doherty et al, 1998).
In this study, we extended these investigations to examine
combination therapy with MMC and D3T in six human tumour
cell lines. D3T increased DT-diaphorase activity in all six cell
lines, and pretreatment with the enzyme inducer significantly
enhanced the cytotoxicity of MMC in four of the cell lines.
Combination treatment with D3T and MMC increased the cyto-
toxic activity of MMC by 2.3-fold in H661 non-small-cell lung
cancer cells, by 2.4-fold in T47D breast cancer cells, by 1.4-fold in
HS578T breast cancer cells and by twofold in HCT116 human
colon cancer cells. These results demonstrate that this combination
treatment is effective in enhancing the cytotoxicity of MMC in
different tumour types. D3T did not increase MMC cytotoxic
activity in SK-MEL-28 melanoma cells or AGS stomach cancer
cells. Both these cell lines have relatively high base levels of DT-
diaphorase activity. This suggests that this combination therapy
approach may be restricted by the level of DT-diaphorase in the
cells. If the base or induced level of DT-diaphorase is above an
upper threshold, further induction may not lead to an increase in
Enhanced MMC cytotoxicity with DT-diaphorase inducers 1227
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Figure 6 Combination therapy with MMC and D3T in normal human
marrow cells. Cells were incubated at 37°C with, or without, 100 mM D3T for
48 h, then were treated with various concentrations of MMC for 1 h. Surviving
cell fraction was measured by methylcellulose clonogenic assay. DT-
diaphorase activity was measured as described in Materials and Methods
and is shown in the inserted figure. Data represent the mean ± s.e.m. of four
to five determinations. The lines are linear regression lines. Two-tailed t-tests
were used to determine the significance of the difference of the DT-
diaphorase activities. (*P < 0.05)MMC cytotoxicity. Our results, and a previous study (Beall et al,
1995), suggest that this upper threshold may be close to 300 nmol
min–1 mg protein–1. While this may limit the use of this combina-
tion therapy approach in some situations, it should not signifi-
cantly impair the use of DT-diaphorase inducers to increase the
anti-tumour activity of bioreductive agents in the clinic since
primary tumours generally have base levels of DT-diaphorase that
are <100 nmol min–1 mg protein–1 (Schlager and Powis, 1990;
Malkinson et al, 1992; Ross et al, 1994; Smitskamp-Wilms et al,
1995; Marin et al, 1997).
To further improve the clinical potential of this treatment strategy
for increasing the activity of bioreductive agents, we investigated
dietary components and some pharmaceuticals as non-toxic
inducers of DT-diaphorase. Fourteen compounds were tested for
their ability to induce DT-diaphorase in T47D cells, a cell line that
has been shown to be readily inducible and has a relatively low base
level of DT-diaphorase. Eight of the 14 compounds significantly
increased DT-diaphorase activity with some of the compounds
proving to be better inducers than D3T. DMM and DMF were the
best inducers studied and produced fivefold increases in enzyme
activity. These compounds are metabolites of fumaric and maleic
acid that are commonly found in foods. Sulforaphane, which is
extracted from broccoli and has been extensively studied as a potent
chemopreventive agent, showed good enzyme induction, and PG, an
antioxidant added to foods, produced a 2.5-fold increase in enzyme
activity. Although some vitamins have been shown to increase DT-
diaphorase activity (Wang and Higuchi, 1995), only 13-cis-retanoic
acid was able to induce DT-diaphorase in T47D cells. There has
been great interest in non-steroidal anti-inflammatory drugs
(NSAIDs) in cancer prevention, but the mechanisms through which
these agents work is still not clear. Thus, we tested aspirin and
ibuprofen in this study to see if they could increase DT-diaphorase
activity in tumour cells. Aspirin produced a small but significant
induction of DT-diaphorase, but ibuprofen had no effect. Soybeans
1228 X Wang et al
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Table 1 Effect of inducers of DT-diaphorase on the cytotoxicity of MMC in human cells
D0 (mM)
Tumour type Cell line Inducer Control With inducer P-value
Colon HCT116 D3T 3.31 ± 0.25 1.67 ± 0.11 < 0.001
Lung H661 D3T 3.24 ± 0.19 1.43 ± 0.15 < 0.001
Skin SK-MEL-28 D3T 4.40 ± 0.41 4.06 ± 0.34 NS
Stomach AGS D3T 0.78 ± 0.08 0.66 ± 0.05 NS
Breast HS578T D3T 3.72 ± 0.30 2.63 ± 0.10 < 0.01
Breast T47D D3T 3.27 ± 0.20 1.34 ± 0.13 < 0.001
Breast T47D DMM 3.27 ± 0.20 1.13 ± 0.09 < 0.001
Breast T47D PG 3.27 ± 0.20 1.85 ± 0.14 < 0.001
Normal human bone marrow D3T 4.66 ± 0.41 2.95 ± 0.23 < 0.05
Cells were treated with, or without, inducers at 37°C for 48 h, then were incubated with various concentrations of MMC for 1 h. Surviving cell fractions were
measured by MTT assay for tumour cells or by methylcellulose clonogenic assay for normal marrow cells. The cytotoxic activity of MMC is presented as the D0,
which was obtained from the linear regression line of the surviving cell fraction vs drug concentration curve. The data represent the mean ± s.e.m. of three to
eight determinations. A t-test comparing the significance of the difference of the slopes of the linear regression lines was used to compare the D0 for cells
treated with, or without, inducers. NS, not significant.
Table 2 Induction of DT-diaphorase in T47D human breast cancer cells by dietary inducers
Enzyme activity
Inducers Concentration (nmol min–1 mg protein–1) P-value
Control 27.8± 1.2
D3T 100 mM 101.0± 2.8 <0.001
13-cis-retinoic acid 10 mM 61.6 ± 4.9 <0.001
Genistein 5 mM 23.8 ± 1.4 NS
Ursolic acid 15 mM 29.6 ± 4.4 NS
Chalcone 20 mM 41.4 ± 3.4 <0.001
Aspirin 1 mM 40.8 ± 1.2 <0.001
Ibuprofen 200 mM 16.1 ± 1.1 NS
Caffeic acid 500 mM 33.4 ± 2.3 NS
Folic acid 100 mM 17.3 ± 2.5 NS
Vitamin K 10 mM 17.3 ± 1.3 NS
Dimethyl maleate (DMM) 50 mM 121.0 ± 3.9 <0.001
Propyl gallate (PG) 10 mM 80.5 ± 5.3 <0.001
Dimethyl fumarate (DMF) 50 mM 128.5 ± 5.6 <0.001
Sulforaphane 10 mM 102.3 ± 0.7 <0.001
Cells were incubated with, or without, inducers at the concentrations shown at 37°C for 48 h. Cells were washed, pelleted, suspended
in 200 ml of 0.25 M sucrose and sonicated. DT-diaphorase activity was measured using menadione as the electron acceptor. Data
represent the mean ± s.e.m. of three to five determinations. Two-tailed t-tests were used to compare the significance of the difference
of DT-diaphorase activity in control and inducer-treated cells. NS not significant.have been shown to increase phase II enzymes, including DT-
diaphorase, in rats (Appelt and Reicks, 1997); however, genistein,
which is extracted from soybeans, did not increase DT-diaphorase
activity in our study. Manson et a (1997) have shown that caffeic
acid is a moderate inducer of phase II enzymes, but in our study
caffeic acid did not increase DT-diaphorase activity.
To investigate if the level of enhancement of MMC activity is
dependent on the level of DT-diaphorase induction, we carried out
combination therapy studies with PG, D3T and DMM together
with MMC in T47D cells. Pretreatment of cells with these enzyme
inducers increased MMC activity in the order PG < D3T < DMM,
and this paralleled the increase in DT-diaphorase activity. This
suggests that there is a relationship between the level of induction
in enzyme activity and the enhancement of MMC cytotoxicity,
provided the DT-diaphorase activity does not exceed an upper
threshold level. Since primary tumours usually have lower levels
of DT-diaphorase activity than tumour cells grown in vitro, it may
be possible to achieve greater enhancement of anti-tumour activity
of bioreductive agents in the clinic by using more potent inducers
of DT-diaphorase.
Since many enzymes can activate bioreductive anti-tumour
agents, we examined the effect of DMM on enzymes that have
been reported to be involved in MMC activation. When T47D
cells were treated with 50 mM DMM, there were no changes in
NADPH:cytochrome P450 reductase, or NADH:cytochrome b5
reductase activity. Xanthine dehydrogenase activity was too low to
be detected either before or after DMM treatment. GST is a phase
II enzyme that can be induced coordinately with DT-diaphorase.
This enzyme can also protect cells from toxins by removing them
from the cell, and has been shown to play a role in resistance to a
number of anti-tumour agents, including MMC (Xu et al, 1994).
Although we did not see an increase in GST activity in HL-60
human leukaemia cells following treatment with 100 mM D3T
(Doherty et al, 1998), in this study there was an increase in GST
activity when T47D cells were treated with DMM. However, the
effect was small and there was still a large enhancement of MMC
cytotoxic activity in these cells.
The major toxicity associated with the use of MMC is bone
marrow toxicity. We have previously shown that D3T did not
increase the toxicity of MMC to mouse bone marrow (Begleiter et
al, 1996). In this study, pretreatment with D3T produced a 1.5-fold
increase in toxicity to human marrow cells; however, this was
small compared with the enhancement of MMC cytotoxic activity
in T47D, H661 and HCT116 cells. This result suggests that combi-
nation therapy with DT-diaphorase inducers and MMC may
increase the therapeutic index for MMC for appropriate tumours.
In addition, DT-diaphorase does not appear to be the major
enzyme involved in activating MMC. Thus, we would expect a
greater increase in therapeutic index if this approach were used
with bioreductive agents that are selectively activated by DT-
diaphorase like E09 (Doherty et al, 1998) or RH1 (Winski et al,
1998). Indeed, we did see a greater enhancement of EO9 cytotoxic
activity compared with MMC in mouse lymphoma cells pretreated
with D3T (Begleiter et al, 1996).
These studies support the hypothesis that inducers of DT-
diaphorase could be used to increase the effectiveness of bioreduc-
tive agents in the clinic; however, a number of concerns must still
be addressed. Activation of bioreductive agents by one-electron
reducing enzymes like NADPH:cytochrome P450 reductase is
increased in the absence of oxygen because redox cycling of the
reduced intermediates is prevented. We have shown that DT-
diaphorase does not contribute to the activation of MMC under
hypoxic conditions (Begleiter et al, 1992), and there is some
evidence that this enzyme may actually decrease the activity of
bioreductive agents under these conditions (Plumb et al, 1994).
Since bioreductive agents have often been used to target hypoxic
cells in solid tumours, induction of DT-diaphorase might result in
decreased anti-tumour activity. However, only a small proportion
of tumour cells in solid tumours are actually anoxic, with most
cells being exposed to at least some levels of oxygen. Marshall and
Rauth (1986) demonstrated that oxygen levels of <1% were suffi-
cient to allow redox cycling and reverse the enhanced MMC cyto-
toxic activity under hypoxic conditions. Thus, increasing the level
of DT-diaphorase is likely to increase the overall anti-tumour
effectiveness of MMC. In addition, the activity of bioreductive
agents that were specifically activated by DT-diaphorase would be
unaffected by the level of oxygen in the tumour cells and would be
increased by induction of DT-diaphorase.
Our studies have demonstrated that induction of DT-diaphorase
can increase the cytotoxic activity of bioreductive agents in many
tumours in vitro (Begleiter et al, 1996; Doherty et al, 1998).
However, Nishiyama et al (1993) found a negative correlation
between DT-diaphorase activity and MMC anti-tumour activity in
vivo. In contrast, Malkinson et al (1992) saw greater MMC
activity in human tumour xenografts with higher DT-diaphorase
activity. Thus, the ability of DT-diaphorase inducers to enhance the
anti-tumour activity of bioreductive agents must still be demon-
strated in vivo. In addition, our findings suggest that this strategy
may not be effective with all tumours, and that for clinical applica-
tion it will be necessary to measure the level of DT-diaphorase and
the inducibility of the enzyme in vitro in tumour biopsy samples
prior to the start of therapy.
In summary, this study has demonstrated that inducers of DT-
diaphorase can selectively increase the cytotoxicity of MMC in
human tumour cells of different tumour type. Enzyme inducers,
including dietary components, that produced more induction of
DT-diaphorase also produced a greater enhancement of MMC
cytotoxic activity. Thus, it may be possible to use non-toxic
inducers of DT-diaphorase to enhance the efficacy of bioreductive
anti-tumour agents.
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